News


All series


All News

Over the last 10 years, the treatment landscape for biliary tract cancers, specifically intrahepatic cholangiocarcinoma, has evolved and now offers physicians more front- and second-line choices for their patients. For targeted agents in this setting, promising new data have come out for patients with actionable alterations.